Therefore, in patients with normal or high expression of MHCI on tumor cells, drugs targeting the MHCI/LILRB1 axis may promote anti-tumor immune responses and play a synergistic effect with drugs targeting CD47/ SIRPα axis. Here, LILRB1 is linked to neoplasm.